A new phase 3 clinical trial of a tuberculosis vaccine called M72 will be conducted in a number of countries including South Africa. The study will be looking at the efficacy of preventing progression from TB infection (also called latent TB) to active pulmonary TB disease.
Read all about it in the Daily Maverick.